Alkaptonuria is a rare inherited metabolic disorder in which the body cannot fully break down two amino acids, tyrosine and phenylalanine, leading to a buildup of a substance called homogentisic acid (HGA) in tissues throughout the body. The condition is caused by mutations in a single gene, and its most recognizable early sign is urine that darkens when exposed to air. Over decades, the accumulated HGA deposits in connective tissue, progressively damaging joints, heart valves, and other organs in ways that can be mistaken for more common diseases.
What Causes Alkaptonuria
Alkaptonuria results from mutations in the HGD gene, which provides instructions for making an enzyme called homogentisate 1,2-dioxygenase.1PubMed Central. Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations This enzyme normally breaks down HGA as part of the body’s routine processing of tyrosine and phenylalanine, amino acids found in nearly all protein-containing foods. When the enzyme is absent or does not work properly, HGA has nowhere to go. It accumulates in the blood, spills into the urine, and gradually deposits in connective tissues throughout the body.2PubMed. Natural history of alkaptonuria
The condition follows an autosomal recessive inheritance pattern, meaning a person needs to inherit a faulty copy of the HGD gene from each parent to develop the disease.3Scientific Reports. Homogentisate 1,2-dioxygenase (HGD) gene variants in young Egyptian patients with alkaptonuria Parents who each carry one mutated copy are typically unaffected themselves. Over a hundred different mutations in the HGD gene have been identified across patients worldwide, which partly explains why the disease can vary in severity from person to person.4PubMed Central. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on ‘black bone disease’ in Italy Alkaptonuria holds a notable place in medical history: it was one of the first four conditions used to define the concept of an “inborn error of metabolism” back in 1908.5Annals of Translational Medicine. Inborn errors of metabolism in the 21st century: past to present
Dark Urine and Other Early Signs
For many families, the first clue comes in infancy or early childhood: a parent notices that the baby’s diaper turns dark brown or black after sitting for a while. This happens because HGA in the urine oxidizes when it comes into contact with air, and the reaction is stronger in alkaline conditions.6PubMed. From darkening urine to early diagnosis of alkaptonuria Darkening urine is often the only visible sign during childhood and adolescence. Children with alkaptonuria generally feel well and have no pain or functional problems. Because the urine color change can be subtle or attributed to other causes, many cases go undiagnosed for years or even decades.
Outside of the urine, the disease is essentially silent in young people. The damaging effects of HGA accumulation take time to develop, and the body’s connective tissues absorb the pigment slowly. This long quiet phase is part of what makes alkaptonuria so tricky: by the time symptoms become noticeable in adulthood, the disease has been at work for a long time.
Ochronosis and What Happens to Connective Tissue
The hallmark feature of alkaptonuria in adults is ochronosis, a process in which HGA undergoes chemical changes and deposits a bluish-black pigment in connective tissues. The pigment accumulates in cartilage, tendons, ligaments, skin, the whites of the eyes, and ear cartilage.7PubMed Central. Blue man: Ochronosis in Otolaryngology You can sometimes see the bluish discoloration on the ears or around the nose in affected individuals, though it tends to be subtle in lighter skin tones and may go unnoticed.
Within joints, the process is more insidious. The calcified cartilage and the tissue lining the cartilage surface appear to be the earliest places where pigment deposits, though researchers still do not fully understand why these specific layers are hit first.8PubMed Central. An anatomical investigation of alkaptonuria: Novel insights into ochronosis of cartilage and bone The pigment makes the cartilage brittle and prone to breakdown, setting the stage for the severe joint disease that defines the condition in later life.
Joint and Spine Problems
The musculoskeletal damage caused by ochronosis is typically the most debilitating aspect of alkaptonuria. Joint disease usually appears in a person’s late twenties to forties and follows a fairly predictable pattern. The lumbar spine tends to be affected first, with pigment deposits in the intervertebral discs causing stiffness and pain.9PubMed. Orthopedic Manifestations of Ochronosis: Pathophysiology, Presentation, Diagnosis, and Management From there, degeneration commonly spreads to the knees, hips, and shoulders.
What distinguishes ochronotic arthropathy from ordinary osteoarthritis is its severity, its early onset, and the pattern of involvement. Patients experience severe joint pain, limited range of motion, swelling, and stiffness, often progressing faster than what doctors would expect for their age.10PubMed Central. Musculoskeletal manifestations of alkaptonuria: A case report and literature review Because alkaptonuria is so rare, clinicians unfamiliar with the condition may initially diagnose these patients with early-onset osteoarthritis or ankylosing spondylitis. Many patients ultimately need joint replacement surgery, sometimes at relatively young ages. The classic triad of the disease is dark urine, bluish-black tissue discoloration, and arthropathy of the spine and large joints.11PubMed Central. Ochronotic arthropathy: skeletal manifestations and orthopaedic treatment
Cardiovascular Complications
The heart and blood vessels are not spared. Ochronotic pigment deposits in heart valves, the lining of the heart, the pericardium, the aorta, and coronary arteries.12PubMed Central. Aortic stenosis and vascular calcifications in alkaptonuria Over time, this can lead to calcification and stiffening of these structures. In a study of 70 alkaptonuria patients, 12 had aortic sclerosis (thickening of the valve) and 7 had progressed to aortic stenosis (narrowing that restricts blood flow). Vascular calcifications were also seen in the coronary arteries, the descending aorta, and the iliac arteries.
Aortic valve stenosis is one of the more serious cardiovascular consequences. The ochronotic deposits make the valve leaflets rigid, eventually requiring surgical replacement in some patients.13PubMed Central. Video-Assisted Minimally Invasive Endoscopic Aortic Valve Replacement in a Patient With Alkaptonuria These cardiovascular problems typically develop later in the disease course, but patient surveys indicate that heart complications rank among the symptoms with the greatest impact on quality of life.14PubMed Central. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care
Kidney and Prostate Stones
The kidneys filter large amounts of HGA from the blood, and the acid’s tendency to crystallize means kidney stones are a recognized complication. Stone formation can occur in the kidneys, ureters, or bladder. Men with alkaptonuria may also develop extensive prostatic calcifications, which tend to be more widespread than the prostate stones seen in more common conditions.15PubMed Central. A rare presentation of alkaptonuria: Extensive prostatic calculi with highlight of stones found in a unique paraprostatic urethral diverticulum These urological complications can cause pain and urinary difficulties and may require surgical intervention.
How Alkaptonuria Is Diagnosed
The gold standard for confirming alkaptonuria is detecting elevated HGA in the urine or blood. HGA acts as a specific diagnostic marker for the condition.16PubMed. Determination of homogentisic acid in urine for diagnosis of alcaptonuria: Capillary electrophoretic method optimization using experimental design Standard laboratory techniques, including chromatography, can measure HGA levels accurately. Researchers have also developed simpler screening approaches. One method involves adding an alkaline solution to dried urine on paper: the color intensity that develops is proportional to the HGA concentration, and the results have been validated against more sophisticated lab techniques. This kind of quick test could help identify patients in regions where advanced lab equipment is less accessible.17PubMed Central. Quick Diagnosis of Alkaptonuria by Homogentisic Acid Determination in Urine Paper Spots
Genetic testing to identify the specific HGD gene mutation can confirm the diagnosis and is useful for family planning, but it is not strictly necessary when the biochemical findings are clear. In practice, many patients are diagnosed only after they develop musculoskeletal or cardiovascular symptoms and a clinician puts together the pattern. A surgeon who notices blackened cartilage during a joint operation, for instance, may be the first to suspect alkaptonuria. The long diagnostic delay is a recurring theme: patient surveys highlight that the path to receiving a correct diagnosis is frequently frustrating and drawn out.14PubMed Central. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care
Tracking Disease Severity
Because alkaptonuria affects so many organ systems, clinicians need a way to measure how far the disease has progressed and whether treatment is helping. A composite scoring tool called the Alkaptonuria Severity Score Index (AKUSSI) was developed for this purpose. It pulls together information on joint disease, eye and ear pigmentation, kidney involvement, and other features into a single severity score.18PubMed Central. Improving the clinical accuracy and flexibility of the Alkaptonuria severity score index The tool has been refined over time and validated as a reliable measure of overall disease burden, though researchers have noted that some of its individual components could be simplified without losing accuracy.19PubMed Central. Alkaptonuria Severity Score Index Revisited: Analysing the AKUSSI and Its Subcomponent Features The AKUSSI played a central role in the clinical trials that led to the approval of the first drug treatment for the condition.
Nitisinone and How It Works
For most of its medical history, alkaptonuria had no specific treatment. That changed with nitisinone, a drug that blocks the enzyme one step earlier in the same metabolic pathway, preventing HGA from being produced in the first place. By shutting down the production of HGA at the source, nitisinone dramatically reduces the amount of acid circulating in the blood and being excreted in the urine.20PubMed. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial
The key evidence came from a large international trial called SONIA 2, which compared 10 mg of nitisinone taken once daily to no treatment over four years. In patients taking nitisinone, urinary HGA dropped by about 99.7% compared with the control group by the 12-month mark. More importantly, over the full four years, the disease severity score (measured by the AKUSSI) increased significantly less in the treated group, with an adjusted difference of about 8.6 points. Nitisinone decreased ochronosis and improved clinical signs, indicating slower disease progression.21The Lancet Diabetes & Endocrinology. Safety and efficacy of nitisinone in patients with alkaptonuria (SONIA 2)
Side Effects of Nitisinone and Managing Them
Nitisinone is not without complications. By blocking HGA production, the drug causes an upstream metabolite, tyrosine, to build up in the blood instead. Elevated tyrosine levels can cause problems of their own, particularly in the eyes. Some patients develop a form of corneal damage called keratopathy, which involves painful, branching lesions on the cornea that resemble those seen in herpes infections. The condition can also cause a thickening skin reaction on the palms and soles.22PubMed Central. Nitisinone-Induced Keratopathy in Alkaptonuria: A Challenging Diagnosis Despite Clinical Suspicion
The encouraging finding is that this keratopathy appears to be reversible. In at least one documented case, a patient who developed corneal changes after starting even a low dose of nitisinone saw complete resolution of the lesion and visual symptoms after the drug was stopped.23PubMed Central. Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report This means regular eye exams are an important part of monitoring for anyone on nitisinone, and catching keratopathy early allows the care team to adjust treatment before permanent damage occurs.
Dietary protein restriction has been explored as a way to keep tyrosine levels in check during nitisinone treatment. In the SONIA 2 trial, patients were advised to lower their protein intake. The study centers where patients had the lowest tyrosine levels and the lowest protein intake (estimated from urinary urea) also had the lowest rates of keratopathy, at around 3%, compared to roughly 15% at the centers with the highest tyrosine levels. The trade-off was that protein restriction led to increased body weight in some patients.24PubMed Central. Effects of a protein-restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria Finding the right balance between lowering tyrosine and maintaining adequate nutrition is an ongoing challenge for patients and their dietitians.
What Daily Life Looks Like
Patient surveys paint a clear picture of what matters most to people living with alkaptonuria. The symptoms with the greatest reported impact are pain and tendon ruptures, disability and difficulty performing daily routines, emotional and mental health challenges, and heart complications.14PubMed Central. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care Joint stiffness can make activities like bending, climbing stairs, or getting dressed genuinely difficult. The chronic pain that develops over years can take a toll on mental health, and the rarity of the disease means patients often feel isolated, encountering doctors who have never heard of their condition.
Supportive care remains an important part of management alongside drug treatment. Physical therapy and exercise help maintain joint mobility and muscle strength. Pain management strategies range from over-the-counter anti-inflammatory medications to more targeted interventions. When joints deteriorate beyond the point where conservative measures help, surgical replacement of hips, knees, and shoulders can restore function, though the darkened, brittle cartilage sometimes presents unique challenges for surgeons unfamiliar with the condition.
Gene Therapy Research
Nitisinone addresses the downstream consequences of alkaptonuria by reducing HGA, but it does not fix the underlying genetic defect. Researchers have begun investigating gene therapy approaches that would aim to restore functional HGD enzyme production, potentially offering a more complete treatment. Early-stage work has used CRISPR gene-editing technology to create laboratory cell models of alkaptonuria in human liver cell lines, providing a way to test gene-replacement strategies without relying entirely on animal models.25PubMed Central. Alkaptonuria: Current Perspectives A mouse model of the disease already exists for this purpose, and the hope is that enzyme replacement or gene therapy could one day correct the metabolic block at its root. These approaches remain in preclinical stages, and no human gene therapy trials for alkaptonuria have been completed, but the groundwork is being laid for what would represent a fundamentally different kind of treatment.
Why Diagnosis Takes So Long
One of the most frustrating aspects of alkaptonuria for patients and their families is how long it often takes to get a correct diagnosis. The disease is rare enough that most general practitioners and even many specialists will never encounter a case. Dark urine in infancy may not be noticed or may be dismissed. Once joint symptoms begin in adulthood, they look superficially similar to ordinary degenerative arthritis, and a 35-year-old with severe back pain is more likely to be investigated for disc herniation than for a metabolic disorder.
The condition sometimes comes to light only incidentally. A surgeon performing knee or hip replacement discovers strikingly dark cartilage and sends tissue for pathological analysis. An ophthalmologist notices bluish pigment in the sclera during a routine eye exam. A urologist investigating recurrent kidney stones finds unusual chemical composition. Each of these moments represents a chance for diagnosis, but only if the clinician recognizes the pattern. Greater awareness of alkaptonuria among healthcare professionals, along with wider availability of simple urine screening methods, could help close the diagnostic gap and get patients started on treatment before decades of tissue damage have already occurred.